Your browser doesn't support javascript.
loading
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan.
Alder, Laura; Trapani, Dario; Bradbury, Claire; Van Swearingen, Amanda E D; Tolaney, Sara M; Khasraw, Mustafa; Anders, Carey K; Lascola, Christopher D; Hsu, Liangge; Lin, Nancy U; Sammons, Sarah.
Afiliação
  • Alder L; Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University, Durham, NC, USA.
  • Trapani D; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Bradbury C; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
  • Van Swearingen AED; Harvard Medical School, Boston, MA, USA.
  • Tolaney SM; Department of Biostatistics, Duke Cancer Institute, Duke University, Durham, NC, USA.
  • Khasraw M; Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University, Durham, NC, USA.
  • Anders CK; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Lascola CD; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
  • Hsu L; Harvard Medical School, Boston, MA, USA.
  • Lin NU; Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University, Durham, NC, USA.
  • Sammons S; Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University, Durham, NC, USA.
NPJ Breast Cancer ; 9(1): 19, 2023 Mar 30.
Article em En | MEDLINE | ID: mdl-36997605

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article